	KEYTRUDA® 200 mg every 3 weeks n=514	Placebo n=505
Men	63%	60%
Women	37%	40%
Age (median)	54 years	54 years
Age (range)	19 - 88 years	19 - 83 years
Age (≥ 65)	24%	25%
ECOG PS		
0	94%	94%
1	6%	6%
Stage		
IIIA (> 1 mm)	16%	16%
IIIB	46%	46%
IIIC (1-3 positive lymph nodes)	18%	18%
IIIC (≥ 4 positive lymph nodes)	20%	20%
BRAF status		
Mutation detected	48%	52%
Mutation not detected	45%	42%
Unknown	7%	6%
PD-L1 status*		
Positive	83%	84%
Negative	11%	11%
Unknown	5%	5%

* Assessed by immunohistochemistry; positive: ≥1% PD-L1; negative: <1% PD-L1; unknown: indeterminate PD-L1.[1]

ECOG PS=Eastern Cooperative Oncology Group performance status; PD-L1 =programmed cell death ligand 1.

Adapted from the KEYTRUDA® Product Monograph.[1]